Reviewing Esperion Therapeutics (ESPR) & Its Competitors
Esperion Therapeutics (NASDAQ: ESPR) is one of 196 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its rivals? We will compare Esperion Therapeutics to related companies based on the strength of its earnings, dividends, institutional ownership, valuation, profitability, risk and analyst recommendations.
Risk and Volatility
Esperion Therapeutics has a beta of 2.69, suggesting that its stock price is 169% more volatile than the S&P 500. Comparatively, Esperion Therapeutics’ rivals have a beta of 1.67, suggesting that their average stock price is 67% more volatile than the S&P 500.
Valuation and Earnings
This table compares Esperion Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Esperion Therapeutics||N/A||-$131.29 million||-8.98|
|Esperion Therapeutics Competitors||$207.14 million||-$2.51 million||0.26|
Esperion Therapeutics’ rivals have higher revenue and earnings than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Insider & Institutional Ownership
83.3% of Esperion Therapeutics shares are held by institutional investors. Comparatively, 47.6% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 32.5% of Esperion Therapeutics shares are held by insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This table compares Esperion Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Esperion Therapeutics Competitors||-3,680.68%||-416.66%||-48.22%|
This is a summary of recent ratings for Esperion Therapeutics and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Esperion Therapeutics Competitors||785||2925||6378||144||2.57|
Esperion Therapeutics presently has a consensus price target of $55.21, indicating a potential upside of 6.31%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 10.41%. Given Esperion Therapeutics’ rivals higher probable upside, analysts plainly believe Esperion Therapeutics has less favorable growth aspects than its rivals.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy. As of December 31, 2016, the Company was engaged in conducting its global Phase III clinical development program for bempedoic acid.
Receive News & Stock Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related stocks with our FREE daily email newsletter.